bsadc

Bispecific ADCs advance oncology. Biointron shows how dual-targeted antibody-drug conjugates improve precision, efficacy, and patient outcomes in cancer treatment.

Bispecific antibody-drug conjugates (BsADCs) are a new class of therapeutic drugs being developed to fight cancer. They combine the dual targeting ability of bispecific antibodies with the cell-killing power of cytotoxic drugs. BsADCs are designed to deliver cytotoxic drugs directly to cancer cells, while minimizing damage to healthy cells. While they are still in development, several exciting advances have occurred recently.